Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of concept-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of concept

Published:2024-07 Issue: Volume:264 Page:110240
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Favi Evaldo,Cresseri Donata,Perego Marta,Ikehata Masami,Iesari Samuele,Campise Maria Rosaria,Morello William,Testa Sara,Sioli Viviana,Mattinzoli Deborah,Longhi Elena,Del Gobbo Alessandro,Castellano Giuseppe,Ferraresso Mariano

Funder

Ministry of Health

Publisher

Elsevier BV

Reference73 articles.

1. Strategies to increase the donor pool and access to kidney transplantation: an international perspective;Maggiore;Nephrol. Dial. Transplant.,2015

2. OPTN/SRTR 2018 annual data report: kidney;Hart;Am. J. Transplant.,2020

3. Current approaches to desensitization in solid organ transplantation;Schinstock;Front. Immunol.,2021

4. Preformed donor-specific HLA antibodies in living and deceased donor transplantation: a multicenter study;Ziemann;Clin. J. Am. Soc. Nephrol.,2019

5. Cumulative mean fluorescent intensities of HLA specific antibodies predict antibody mediated rejections after kidney transplantation;Heinemann;HLA,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming the Hurdle: HLA Mismatch and Desensitization Therapy in Kidney Transplantation;Advances in Kidney Transplantation [Working Title];2024-08-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP